JAK/TYK2

Pedro Castillo _Castillo_Pedro
3 years 6 months ago
Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2
Statistically greater response in axial dz compared to placebo in both dz dx'ed by investigator alone & on investigator + PRO-based criteria
https://t.co/YPc5fx9wAR
#ACR21 Abst1945 @RheumNow

David Liew drdavidliew
3 years 6 months ago
Put those two RF together (essentially nailing down RA pts at risk of cancer):
age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30)
age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24)
neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55)
#ACR21 @RheumNow https://t.co/Uvr4wBhFVF


Eric Dein ericdeinmd
3 years 6 months ago
#ACR21 Ab#1939: Tofa CV Outcome (STAR-RA)
▶️Pooled data does not show ⬆️ risk of CVD
▶️Trend in pts w prior CVD -HR 1.27 (0.95-1.7), cannot r/o CVD risk in pts w risk factors
Less clear than oral surveillance data, but concerns in those w risks
https://t.co/JOKNyYVZfX @Rheumnow https://t.co/GGYJfxcqhc


Richard Conway RichardPAConway
3 years 6 months ago
ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq


David Liew drdavidliew
3 years 6 months ago
STAR-RA, CV risk
large insurance datax3
tofa vs TNFi
all comers: HR 1.01 (0.83-1.23)
one CV RF + any MTX: HR 1.24 (0.90-1.69)
prev CVD: HR 1.27 (0.95-1.70)
not sig
but surely okay to say baseline CV risk + tofa makes me a little nervous?
@SeoyoungCKim #ACR21 ABST1939 @RheumNow https://t.co/LmmL5zgv9u


David Liew drdavidliew
3 years 6 months ago
ORAL Surveillance: MACE and malignancy are getting all the attention...
but did you know that non-zoster infections are also more likely with tofacitinib vs TNFis?
#ACR21 ABST1684 @RheumNow https://t.co/GiBkvPYs4j


Janet Pope Janetbirdope
3 years 6 months ago
Serious infections beyond herpes zoster in both doses of #tofacitinib v #TNFi in Oral Surveillance. Note this outcome was not powered to be stat sig. it is a comparison of SIE events #ACR21 abst#1684 @RheumNow https://t.co/uqME6ABXuC


Katie Poholek kpoho
3 years 6 months ago
Handy overview of Jak/STAT pathways in rheumatic diseases and available inhibitors (Dr. Joost Swart). Happening now in the Pediatrics Hub (New Therapies & Biologic Safety in Pediatric Rheumatology). #ACR21 #pedsrheum https://t.co/i4bYr4GKOP


Dr. Antoni Chan synovialjoints
3 years 6 months ago
Deucravacitinib is a novel, oral, selective TYK2 inhibitor in PsA and selectively mediates specific inflammatory pathways (IL-23, IL-12, Type I IFN). Listen to my interview with Prof. Oliver Fitzgerald on this and his highlights https://t.co/3UJCwbHsLC
@RheumNow #ACR21 Abst#490 https://t.co/OWZDHhcQ9q


Robert B Chao, MD doctorRBC
3 years 6 months ago
Upadacitinib showed similar efficacy in AS pts compared to PsA pts with axial involvement
⭐️PsA pt w/ axial involvement and AS pts with differences in baseline characteristics
#ACR21 @RheumNow
Abs#1802
https://t.co/QvyayelBYU https://t.co/50dNQm30vf


Dr. Antoni Chan synovialjoints
3 years 6 months ago
Phase 2 Placebo/Deucravacitinib 6mg/12mg od study ACR20 at 16 weeks of 31.8%/52.9%/62.7% respectively. Efficacy observed across TNFi and body weight subgroups. Safety profile similar to Phase 3 trials in patients with psoriasis @RheumNow #ACR21 Abst#1820 https://t.co/bOfEZdqN5Z https://t.co/EjMwWISM80
